{"id":"W4387950784","doi":"10.2217/fon-2023-0526","title":"TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Olaparib; Placebo; Androgen deprivation therapy; Clinical trial; Androgen receptor; Cancer; Poly ADP ribose polymerase; Gene; Pathology; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004813264,0.002590483,0.002989067,0.0005472091,0.001318495,0.002224885,0.002555102,0.003789631,0.0460971],"category_scores_gemma":[0.003421827,0.001262765,0.001282789,0.0008318623,0.001151897,0.001797839,0.0007957834,0.005912058,0.0114277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001989493,"about_ca_system_score_gemma":0.007968955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001577103,"about_ca_topic_score_gemma":0.007986011,"domain_scores_codex":[0.9987458,0.0005851883,0.00008562968,0.0001896762,0.0001664831,0.0002272238],"domain_scores_gemma":[0.9982899,0.0001836861,0.0003131664,0.0001824043,0.0002616319,0.0007691637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8297661,0.02079126,0.00148242,0.004027182,0.001096017,0.0003197918,0.0002657404,0.002089241,0.009668626,0.003353112,0.07942329,0.04771734],"study_design_scores_gemma":[0.9038705,0.04077351,0.002804447,0.0003114513,0.0002850964,0.0001605442,0.00005447998,0.001323032,0.001023597,0.001393777,0.04795435,0.00004514775],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1372633,0.007553805,0.008758244,0.005512243,0.003165196,0.7267165,0.05447811,0.001717829,0.05483481],"genre_scores_gemma":[0.199969,0.005629554,0.01356596,0.0113687,0.00126382,0.6851442,0.02945233,0.000290845,0.05331558],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.0460971,"threshold_uncertainty_score":0.1542102,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1308447482002217,"score_gpt":0.5230714336123913,"score_spread":0.3922266854121696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}